Endosense has announced that the results of its EFFICAS I prospective multi-center study have led to the development of guidelines for target and minimum contact force (CF), as well as minimum Force Time Integral (FTI), during the catheter ablation treatment of paroxysmal atrial fibrillation (PAF).

iRhythm Technologies Inc. announced clinical study findings showing that use of the Zio Patch resulted in a change in treatment strategy for nearly one-third of patients with paroxysmal atrial fibrillation (AF). The data, which was published in Pacing and Clinical Electrophysiology (PACE) Journal on March 12, showed that the Zio Patch ambulatory cardiac monitoring system demonstrated improved clinical accuracy and detection of potentially malignant arrhythmias in AF patients compared with a 24-hour Holter monitor in the same patients.

CHAMPION PHOENIX clinical study anti-platelet therapy cangrelor ACC 13

The experimental anti-clotting drug cangrelor solidly outperformed commonly used clopidogrel in a large global trial of patients who underwent coronary stent procedures, according to data from the phase III CHAMPION PHOENIX study presented at the American College of Cardiology’s 62nd Annual Scientific Session.

 

BioControl Medical has received U.S. Food and Drug Administration (FDA) approval to begin the third and largest phase of INOVATE-HF (INcrease Of VAgal TonE in Heart Failure), a global, multi-center, investigational device exemption (IDE) clinical study of the company’s CardioFit system for heart failure. The approval, which is based on the FDA’s safety review of the first two successful completed phases, allows unconditional study expansion to full enrollment of 650 patients at 80 centers worldwide.

An RTI International-developed prototype catheter that can generate live, streaming 3-D ultrasound images from inside the heart received a Cardiovascular Innovation Award at the 2013 Cardiovascular Research Technologies Annual Symposium.

Cardiac Science, Mortara, Burdick, ECG

Cardiac Science is selling its diagnostic cardiology product line to Mortara Instrument Inc. The business consists of the Burdick and Quinton brands and associated products. The transaction does not include MySense, the novel, wearable, single-patient ECG recorder system or the resuscitation business unit, which markets automated external defibrillators (AEDs) worldwide.

Barco announces the launch of its new Eonis clinical display family. Designed with clinical specialists in mind, the Eonis displays combine an innovative, built-in front sensor with Barco’s MediCal QAWeb cloud-based tool to ensure superior, controlled image quality. The Eonis 22-inch model is available in a black and a white version, with the latter offering a fully cleanable front glass panel to prevent infection – a first in the market.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now